

SUMMARY OF ANALYSIS (SAMPLE ID: SA28863)

Testing Location: Arkansas 232 S. Broadview St. Greenbrier, AR 72058 ADH License: 113	Customer ID: 2061 MaxVera LLC. 12127 Suite L Blue Ridge Extension Grandview MO. 64030	Order ID: OR9015 Lot Number: LOT#0820344603 Batch Number: Not Entered	Sample Type: Primary Matrix: Lotion/Salve Mass: 50g Date Collected: 08/14/2020 Date Received: 08/14/2020
Cultivar (Strain) or Sample Description: 1000mg Pain Cream Airless Pump Nano CBD			Date Completed: 08/19/2020

*This page is simply a summary of the analysis performed. For analytical details, please consult the individual Certificate(s) of Analysis for each of the specific test(s) performed.


*For Oklahoma, with the new OMMA rules to be effective April 1, 2020, limits on moisture are proposed at 15% and water activity at 0.65aw.

Moisture Content (%) Not Tested	PASS/FAIL N/A	Water Activity (aw) Not Tested	PASS/FAIL N/A
---	-------------------------	--	-------------------------

Cannabinoids (Top 3)	(%)	mg/g
CBD	1.16	12
CBG	0.0291	0.291
CBDa	0	-
TOTAL CBD	1.16	12
TOTAL THC	-	-
TOTAL CANNABINOIDS	1.19	12

Terpenes (Top 5)	(%)	µg/g
Isopulegol	0.246	2462
β-Caryophyllene	0.032	323
trans-Nerolidol	0.026	258
Caryophyllene oxide	0.021	207
Linalool	0.018	180
TOTAL TERPENES	0.388	3883

Contaminants	PASS/FAIL
Visual Inspection:	PASS



This information is provided as a service and makes no claims of efficacy and/or safety of this product. Results are applicable only for the sample(s) analyzed and for the specific analysis conducted. This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms. The statements and results herein have not been approved and/or endorsed by the FDA.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of Felling Analytical Services and Technology (F.A.S.T.), LLC

Kyle W. Felling
Kyle W. Felling, Ph.D.
Laboratory Director

CERTIFICATE OF ANALYSIS (SAMPLE ID: SA28863)

Testing Location: Arkansas 232 S. Broadview St. Greenbrier, AR 72058 ADH License: 113	Customer ID: 2061 MaxVera LLC. 12127 Suite L Blue Ridge Extension Grandview MO. 64030	Order ID: OR9015 Lot Number: LOT#0820344603 Batch Number: Not Entered	Sample Type: Primary Matrix: Lotion/Salve Mass: 50g Date Collected: 08/14/2020 Date Received: 08/14/2020
Cultivar (Strain) or Sample Description: 1000mg Pain Cream Airless Pump Nano CBD			Date Completed: 08/19/2020


CANNABINOID (POTENCY) PROFILE

Analysis Date/Time: 08/14/2020 2055
Analyst: PW

Method: HPLC/DAD
Instrument: Agilent 1100

Moisture Content (%): -
Water Activity (aw): -


<u>Cannabinoid</u>	<u>Result (%)</u>	<u>Result (mg/g)</u>	<u>Reporting Limit (mg/g)</u>	<u>Result (mg/mL)</u>	<u>Per Unit (mg)</u>
CBD	1.16	11.6	0.0249	-	1048
CBDa	-	-	0.0249	-	-
CBDv	-	-	0.0249	-	-
Δ9-THC	-	-	0.0249	-	-
Δ8-THC	-	-	0.0249	-	-
THCa	-	-	0.0249	-	-
THCv	-	-	0.0249	-	-
CBC	-	-	0.0249	-	-
CBG	0.0291	0.291	0.0249	-	26
CBGa	-	-	0.0249	-	-
CBN	-	-	0.0249	-	-
TOTAL	1.19	12		-	1075
TOTAL THC	-	-		-	-
TOTAL CBD	1.16	12		-	1048



UNIT MASS (g): 90

"-" Not detected above RL.

Cannabinoid Distribution (% of Total Cannabinoids)



Deviations from standard operating procedure: None

Recoveries for all analyte standards: 90-110%
Replicate Uncertainties: <5% RSD, <20% RPD
Sample/Reagent Blanks: <RL for all analytes

Values for plant matter are adjusted for moisture content.

Total THC = (THCa x 0.877) + Δ9-THC
Total CBD = (CBDa x 0.877) + CBD

Percentage results are reported by mass.
mg/g results are reported as mass component per mass material.

Abbreviations: UV - Ultraviolet, HPLC - High Pressure Liquid Chromatography, RL - Reporting Limit, RPD - Relative Percent Difference, RSD - Relative Standard Deviation

This information is provided as a service and makes no claims of efficacy and/or safety of this product. Results are applicable only for the sample(s) analyzed and for the specific analysis conducted. This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms. The statements and results herein have not been approved and/or endorsed by the FDA.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of Felling Analytical Services and Technology (F.A.S.T.), LLC

Kyle W. Felling
Kyle W. Felling, Ph.D.
Laboratory Director

www.FASTLaboratories.com




SUMMARY OF ANALYSIS (SAMPLE ID: SA28863)

Testing Location: Arkansas 232 S. Broadview St. Greenbrier, AR 72058 ADH License: 113	Customer ID: 2061 MaxVera LLC. 12127 Suite L Blue Ridge Extension Grandview MO. 64030	Order ID: OR9015 Lot Number: LOT#0820344603 Batch Number: Not Entered	Sample Type: Primary Matrix: Lotion/Salve Mass: 50g Date Collected: 08/14/2020 Date Received: 08/14/2020
Cultivar (Strain) or Sample Description: 1000mg Pain Cream Airless Pump Nano CBD			Date Completed: 08/19/2020

TERPENOID PROFILE

Analysis Date/Time: 08/14/2020 2055 **Method:** HS/GC/FID (Internal Method-002) **Deviations from SOP:**
Analyst: KF **Instrument:** Agilent 6890 None

<u>Terpene</u>	<u>Result (µg/g)</u>	<u>Result (%)</u>	
α-Bisabolol	166	0.0166	■
Camphene	-	-	
δ-3-Carene	-	-	
β-Caryophyllene	323	0.0323	■
Caryophyllene oxide	207	0.0207	■
p-Cymene	-	-	
Eucalyptol	-	-	
Geraniol	92	0.00924	■
Guaiol	-	-	
α-Humulene	120	0.012	■
Isopulegol	2462	0.246	■
d-Limonene	-	-	
Linalool	180	0.018	■
β-Myrcene	-	-	
cis-Nerolidol	74	0.00735	■
trans-Nerolidol	258	0.0258	■
α-Ocimene	-	-	
β-Ocimene	-	-	
α-Pinene	-	-	
β-Pinene	-	-	
α-Terpinene	-	-	
γ-Terpinene	-	-	
Terpinolene	-	-	
TOTAL	3883	0.388	



Abbreviations: HS - Headspace, GC - Gas Chromatography, MS - Mass Spectrometry, RL - Reporting Limit

This information is provided as a service and makes no claims of efficacy and/or safety of this product.

Results are applicable only for the sample(s) analyzed and for the specific analysis conducted.

This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms.

The statements and results herein have not been approved and/or endorsed by the FDA.

"-" Not detected above RL.

Reporting Limit (µg/g): -

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of Felling Analytical Services and Technology (F.A.S.T.), LLC

Kyle W. Felling
Kyle W. Felling, Ph.D.
Laboratory Director